Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Am Heart J
    April 2024
  1. HEERSPINK HJ, Provenzano M, Vart P, Jongs N, et al
    Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
    Am Heart J. 2024;270:125-135.
    >> Share

    March 2024
  2. ANAND SS, Aboyans V, Bosch J, Debus S, et al
    Identifying the highest risk vascular patients: Insights from the XATOA registry.
    Am Heart J. 2024;269:191-200.
    >> Share

  3. HAMO CE, Schlamp F, Drenkova K, Jindal M, et al
    Burden of cardiometabolic risk factors and vascular health.
    Am Heart J. 2024;269:201-204.
    >> Share

    February 2024
  4. RAO VN, Sharma A, Stebbins A, Buse JB, et al
    Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00040-1. doi: 10.1016/j.ahj.2024.
    >> Share

    November 2023
  5. SALAHUDDIN T, Hebbe A, Daus M, Essien UR, et al
    Trends and Site-level Variation of Novel Cardiovascular Medication Utilization among Patients Admitted for Heart Failure or Coronary Artery Disease in the US Veterans Affairs System: 2017-2021.
    Am Heart J. 2023 Nov 11:S0002-8703(23)00318-6. doi: 10.1016/j.ahj.2023.
    >> Share

    September 2023
  6. NICHOLLS SJ, Bhatt DL, Buse JB, Prato SD, et al
    Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics.
    Am Heart J. 2023 Sep 25:S0002-8703(23)00280-6. doi: 10.1016/j.ahj.2023.
    >> Share

    August 2023
  7. JAMES S, Erlinge D, Storey RF, McGuire DK, et al
    Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00207-7. doi: 10.1016/j.ahj.2023.
    >> Share

  8. HARRINGTON J, Mentz RJ, Rockhold FW, Garg J, et al
    Baseline Characteristics of Patients in the Randomized Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency: HEART-FID Trial.
    Am Heart J. 2023 Aug 18:S0002-8703(23)00202-8. doi: 10.1016/j.ahj.2023.
    >> Share

    July 2023
  9. WILLIAMS BA, Rajpura J, Paprocki YM, Kumar N, et al
    Temporal Trends in Cardiovascular Outcomes and Costs Among Patients with Type 2 Diabetes.
    Am Heart J. 2023 Jul 27:S0002-8703(23)00185-0. doi: 10.1016/j.ahj.2023.
    >> Share

    May 2023
  10. ARNOLD SV, Gosch K, Kosiborod M, Wong ND, et al
    Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes. Insights from The Diabetes Collaborative Registry.
    Am Heart J. 2023 May 8:S0002-8703(23)00112-6. doi: 10.1016/j.ahj.2023.
    >> Share

    April 2023
  11. DA FONSECA SF, Pinho Ribeiro AL, Rodrigues Cimini CC, de Castro Soares TB, et al
    Scale up of implementation of a multidimensional intervention to enhance hypertension and diabetes care at the primary care setting: a protocol for a cluster-randomized study in Brazil.
    Am Heart J. 2023 Apr 10:S0002-8703(23)00092-3. doi: 10.1016/j.ahj.2023.
    >> Share

    March 2023
  12. GNUDI L, Fountoulakis N, Panagiotou A, Corcillo A, et al
    Effect of active vitamin-D on left ventricular mass index: results of a randomised controlled trial in type 2 diabetes and chronic kidney disease.
    Am Heart J. 2023 Mar 17:S0002-8703(23)00062-5. doi: 10.1016/j.ahj.2023.
    >> Share

    February 2023
  13. KAUL U, Arambam P, Sinha SK, Abhaichand R, et al
    Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
    Am Heart J. 2023;256:128-138.
    >> Share

    December 2022
  14. TANG X, Lingzhu Y, Xing Z
    Predicted lean body mass, fat mass, and heart failure in patients with type 2 diabetes mellitus.
    Am Heart J. 2022 Dec 14:S0002-8703(22)00328-3. doi: 10.1016/j.ahj.2022.
    >> Share

  15. HORIUCHI Y, Matsue Y, Nogi K, Onitsuka K, et al
    Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial.
    Am Heart J. 2022 Dec 8:S0002-8703(22)00325-8. doi: 10.1016/j.ahj.2022.
    >> Share

    November 2022
  16. JANUZZI JL JR, Butler J, Prato SD, Ezekowitz JA, et al
    Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy.
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00287.
    >> Share

    October 2022
  17. NELSON AJ, Pagidipati NJ, Kelsey MD, Ardissino M, et al
    COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) - Diabetes: Rationale and Design.
    Am Heart J. 2022 Oct 21. pii: S0002-8703(22)00274.
    >> Share

  18. LAMAS GA, Anstrom KJ, Navas-Acien A, Boineau R, et al
    The trial to assess chelation therapy 2 (TACT2): Rationale and design.
    Am Heart J. 2022;252:1-11.
    >> Share

    September 2022
  19. DESAI RJ, Glynn RJ, Everett BM, Schneeweiss S, et al
    Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
    Am Heart J. 2022 Sep 20. pii: S0002-8703(22)00193.
    >> Share

    July 2022
  20. SUZUKI Y, Kaneko H, Yano Y, Okada A, et al
    Glycemic status and the association of change in blood pressure with incident cardiovascular disease.
    Am Heart J. 2022 Jul 21. pii: S0002-8703(22)00148.
    >> Share

    May 2022
  21. HARRINGTON J, Udell JA, Jones WS, Anker SD, et al
    Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial.
    Am Heart J. 2022 May 17. pii: S0002-8703(22)00095.
    >> Share

    March 2022
  22. DUCROCQ G, Bhatt DL, Lee JJ, Kui N, et al
    Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ti
    Am Heart J. 2022 Mar 20. pii: S0002-8703(22)00055.
    >> Share

  23. GENEREUX P, Chernin G, Assali AR, Peruga JZ, et al
    Double-Blind, Placebo-Controlled Evaluation of Biorest Liposomal Alendronate in Diabetic Patients Undergoing PCI: The BLADE-PCI Trial: The BLADE-PCI Trial.
    Am Heart J. 2022 Mar 16. pii: S0002-8703(22)00052.
    >> Share

    January 2022
  24. PLUTZKY J, Benson MD, Chaney K, Bui TV, et al
    Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.
    Am Heart J. 2022;243:15-27.
    >> Share

    December 2021
  25. RIFAI MA, Mahtta D, Ramsey DJ, Lee MT, et al
    nCorrelates of SGLT-2-inhibitiors Use Among Patients with Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus: Insights from the Department of Veterans Affairs.
    Am Heart J. 2021 Dec 27. pii: S0002-8703(21)00480.
    >> Share

    October 2021
  26. ARNOLD SV, Khunti K, Tang F, Chen H, et al
    Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes: Results from the Longitudinal Global DISCOVER Study.
    Am Heart J. 2021 Oct 16. pii: S0002-8703(21)00433.
    >> Share

  27. WEAVER AM, McGuinn LA, Neas L, Devlin RB, et al
    Associations between neighborhood socioeconomic cluster and hypertension, diabetes, myocardial infarction, and coronary artery disease within a cohort of cardiac catheterization patients.
    Am Heart J. 2021 Oct 2. pii: S0002-8703(21)00243.
    >> Share

  28. SANDHU AT, Kohsaka S, Lin S, Woo CY, et al
    Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
    Am Heart J. 2021;240:46-57.
    >> Share

  29. COTTER G, Davison BA, Edwards C, Senger S, et al
    Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Am Heart J. 2021;240:73-80.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016